An Extension Study of a Second Course of a Digital Therapeutic for the Treatment of Experiential Negative Symptoms of Schizophrenia

Part of paid clinical trials in New York, New York.

Sponsor
Click Therapeutics, Inc.
Study ID
NCT06067984
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Study App — DEVICE
    An investigational prescription digital therapeutic in the form of a smartphone app.

Study Details

The purpose of the proposed an open label extension (OLE) study is to evaluate the maintained efficacy and safety of a second consecutive course of Click Therapeutics Study App as an adjunct treatment to standard of care (SOC) in participants who were on the Study App and have recently completed the Click Therapeutics Randomized Clinical Trial NCT05838625.

Key Dates

Start date
Sep 12, 2023
Status verified
Jun 2026
Primary completion
Jun 13, 2025
Completion
Aug 22, 2025

Study Design

Enrollment
73 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Arm A
    Evaluate the efficacy and safety of a digital therapeutic as an adjunct treatment to SOC in participants with experiential negative symptoms of schizophrenia.

Primary Outcome Measure

Change in Experiential Negative Symptoms [ Time Frame: Baseline to Week 16 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Click TherapeuticsNew YorkNew York10013-

Find similar trials in New York, NY

By condition
Schizophrenia
By specialty
PsychiatryMental healthBehavioral health
By research site
Click Therapeutics· New York, NY

Related Studies